Thank You

Industry
Researchers
Clinicians
Patients & Families
Advocacy Groups
Our Programs
- - - PROGRAMS
    - PrOSPeCT
    - Omico’s landmark national precision oncology initiative and the largest cancer genomics initiative in Australia. Through a nationally coordinated platform, it expands access to precision oncology, accelerates research, generates real-world data and helps improve cancer care.
    - Cancer Screening Program (CaSP)
    - The screening program associated with PrOSPeCT, providing comprehensive genomic profiling and matching eligible patients with advanced, incurable and poor-prognosis cancers to innovative clinical trials and treatment options.
    - Molecular Screening and Therapeutics (MoST) study
    - The pioneering study that laid the foundation for PrOSPeCT, using genomic profiling to understand molecular changes in cancer and match patients with biomarker-led therapies. Recruitment has closed and follow-up research continues.
    - Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+)
    - Investigating and evaluating the surveillance practices used for people at high-risk of multi-organ cancer.
    - Genetic Cancer Risk in the Young (RisC) study – Now closed
    - Studying genetic variants that contribute to inherited cancer risk in young people. Recruitment has closed and follow-up research continues.
  - - CLINICAL TRIALS
    - Company Studies (C3)
    - Companion Studies (C2)
    - MoST Core Studies (C1)
    - MoST-LLy
    - ASPiRATION
Our RWD Offerings
- - - Our Real-World Data Offerings
    - Based on a unique real-world genomic dataset, built for precision oncology decisions
    - Our Biospecimens for Research
    - Access to biospecimens and associated clinical and genomic data to support research and enable discovery in precision oncology
Resources & Events
About Us
News
Contact

Events & Resources
About Us
News
Contact Us

Sign up for newsletter

Thank you for signing up to Omico’s newsletter. We look forward to keeping you informed.

Privacy Policy
Omico is registered not-for-profit company
Site Map
Sign Up for Newsletter

PROGRAMS

CLINICAL TRIALS

Thank you